Company profile: Aurealis Therapeutics
1.1 - Company Overview
Company description
- Provider of cell and gene therapies for chronic wounds and complex inflammatory diseases. Its four-in-one biologic AUP-16 is a genetically engineered Lactococcus cremoris producing therapeutic proteins to halt inflammation, induce blood vessel growth, and promote tissue formation for diabetic foot, venous leg, and pressure ulcers. AUP-55 is in pre-clinical development for ovarian and bladder cancer.
Products and services
- Clinical Development Programs: Clinical-phase initiatives architected to achieve faster healing in non-healing wounds, targeting Phase 2 clinical efficacy data in diabetic foot ulcers and non-clinical proof-of-concept data in inflammatory diseases
- AUP-16: A four-in-one biologic drug with genetically engineered Lactococcus Cremoris, custom-engineered, produces proteins that halt inflammation, induce blood vessel growth, promote tissue formation in diabetic foot, venous leg, and pressure ulcers
- AUP-55: A preclinical-stage cell and gene therapy product in development that modulates the tumor micro-environment and activates the anti-tumor immune response to treat ovarian and bladder cancers
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Aurealis Therapeutics
IDEC Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapy development targeting neurodegenerative, hematologic, and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IDEC Pharmaceuticals company profile →
Fabrus
HQ: United States
Website
- Description: Provider of functional therapeutic monoclonal antibody discovery and development targeting challenging cell surface proteins, including GPCRs and ion channels, supported by a unique antibody discovery platform and multiple preclinical lead candidates against important cancer targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fabrus company profile →
Ikonisys
HQ: United States
Website
- Description: Provider of fully automated microscopy platforms and FISH-based diagnostic applications for early, accurate, non-invasive disease detection, including Ikoniscope20 for rare-cell detection and Ikoniscope20max with high-volume slide loading, plus oncoFISH solutions for bladder cancer (urine), HER2 status, cervical 3q26 gain in LSIL/ASCUS, and ALK gene rearrangements in non-small cell lung carcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikonisys company profile →
Tube Pharma
HQ: Austria
Website
- Description: Provider of biopharmaceutical research and development focused on cancer medicines, conducting pharmaceutical R&D for pancreatic, lung, and breast cancers, and collaborating with academic institutions and other biopharmaceutical companies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tube Pharma company profile →
Nerviano Medical Sciences
HQ: Italy
Website
- Description: Provider of oncology research and development services, including drug discovery, preclinical research, clinical development, and manufacturing, serving local and international markets. Offers Entrectinib, a kinase inhibitor for ROS1 fusion–positive lung cancer and NTRK gene fusion solid tumors, designed to cross the blood–brain barrier and address CNS metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nerviano Medical Sciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Aurealis Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Aurealis Therapeutics
2.2 - Growth funds investing in similar companies to Aurealis Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Aurealis Therapeutics
4.2 - Public trading comparable groups for Aurealis Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →